284 related articles for article (PubMed ID: 30551474)
1. Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.
Jendželovský R; Jendželovská Z; Kuchárová B; Fedoročko P
Biomed Pharmacother; 2019 Jan; 109():2173-2181. PubMed ID: 30551474
[TBL] [Abstract][Full Text] [Related]
2. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells.
Jendzelovský R; Mikes J; Koval' J; Soucek K; Procházková J; Kello M; Sacková V; Hofmanová J; Kozubík A; Fedorocko P
Photochem Photobiol Sci; 2009 Dec; 8(12):1716-23. PubMed ID: 20024169
[TBL] [Abstract][Full Text] [Related]
3. Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells.
Šemeláková M; Jendželovský R; Fedoročko P
Biomed Pharmacother; 2016 Jul; 81():38-47. PubMed ID: 27261575
[TBL] [Abstract][Full Text] [Related]
4. Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells.
Jendželovská Z; Jendželovský R; Hiľovská L; Kovaľ J; Mikeš J; Fedoročko P
Toxicol In Vitro; 2014 Oct; 28(7):1259-73. PubMed ID: 24994473
[TBL] [Abstract][Full Text] [Related]
5. Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells.
Baglo Y; Liang BJ; Robey RW; Ambudkar SV; Gottesman MM; Huang HC
Cancer Lett; 2019 Aug; 457():110-118. PubMed ID: 31071369
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism.
Lin S; Lei K; Du W; Yang L; Shi H; Gao Y; Yin P; Liang X; Liu J
Int J Biochem Cell Biol; 2016 Feb; 71():24-34. PubMed ID: 26673998
[TBL] [Abstract][Full Text] [Related]
7. The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing.
Choi BH; Ryoo IG; Kang HC; Kwak MK
PLoS One; 2014; 9(9):e107158. PubMed ID: 25226504
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.
Usuda J; Tsunoda Y; Ichinose S; Ishizumi T; Ohtani K; Maehara S; Ono S; Tsutsui H; Ohira T; Okunaka T; Furukawa K; Sugimoto Y; Kato H; Ikeda N
Lung Cancer; 2010 Feb; 67(2):198-204. PubMed ID: 19477032
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status.
Kuchárová B; Mikeš J; Jendželovský R; Vargová J; Mikešová L; Jendželovská Z; Kovaľ J; Fedoročko P
Photodiagnosis Photodyn Ther; 2015 Sep; 12(3):490-503. PubMed ID: 26003114
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
14. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
15. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
16. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
17. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
[TBL] [Abstract][Full Text] [Related]
18. The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP.
Ambjørner SEB; Wiese M; Köhler SC; Svindt J; Lund XL; Gajhede M; Saaby L; Brodin B; Rump S; Weigt H; Brünner N; Stenvang J
Cells; 2020 Mar; 9(3):. PubMed ID: 32143347
[TBL] [Abstract][Full Text] [Related]
19. Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazine.
Biteghe FAN; Padayachee E; Davids LM; Chalomie NET; Ndong JC; Barth S
J Photochem Photobiol B; 2020 Oct; 211():111982. PubMed ID: 32866820
[TBL] [Abstract][Full Text] [Related]
20. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
Lee HJ; Choi CH
BMC Cancer; 2022 Apr; 22(1):446. PubMed ID: 35461219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
